These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 2725334)

  • 1. Progestogen addition during oestrogen replacement therapy--effects on vasomotor symptoms and mood.
    Holst J; Bäckström T; Hammarbäck S; von Schoultz B
    Maturitas; 1989 Mar; 11(1):13-20. PubMed ID: 2725334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peripheral vasomotor control and menopausal flushing--a preliminary report.
    Brincat M; de Trafford JC; Lafferty K; Studd JW
    Br J Obstet Gynaecol; 1984 Nov; 91(11):1107-10. PubMed ID: 6498125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relation between plasma hormone profiles, symptoms, and response to oestrogen treatment in women approaching the menopause.
    Chakravarti S; Collins WP; Thom MH; Studd JW
    Br Med J; 1979 Apr; 1(6169):983-5. PubMed ID: 219937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endometrial effects of a continuous percutaneous oestrogen/low dose oral progestogen regimen for climacteric complaints.
    Holst J; Cajander S; von Schoultz B
    Maturitas; 1987 Apr; 9(1):63-7. PubMed ID: 3110563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical study comparing the effects of sequential hormone replacement therapy with oestradiol/dydrogesterone and conjugated equine oestrogen/norgestrel on lipids and symptoms.
    Cieraad D; Conradt C; Jesinger D; Bakowski M
    Arch Gynecol Obstet; 2006 May; 274(2):74-80. PubMed ID: 16491367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Percutaneous oestrogen therapy opposed by lynestrenol or natural progesterone--effects on circulating oestrogens, FSH, sex hormone binding globulin and pregnancy zone protein.
    Holst J; Cajander S; Carlström K; Damber MG; von Schoultz B
    Maturitas; 1983 Jun; 5(1):1-8. PubMed ID: 6410156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids.
    Rozenberg S; Ylikorkala O; Arrenbrecht S
    Int J Fertil Womens Med; 1997; 42 Suppl 2():376-87. PubMed ID: 9397385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormonal and non-hormonal interventions for menopausal symptoms.
    Coope J
    Maturitas; 1996 Mar; 23(2):159-68. PubMed ID: 8735354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of a novel vaginal ring delivering oestradiol acetate on climacteric symptoms in postmenopausal women.
    Buckler H; Al-Azzawi F;
    BJOG; 2003 Aug; 110(8):753-9. PubMed ID: 12892687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of two years' estrogen-gestagen replacement on climacteric symptoms and gonadotropins in the early postmenopausal period.
    Hagen C; Christensen MS; Christiansen C; Stocklund KE; Transbøl I
    Acta Obstet Gynecol Scand; 1982; 61(3):237-41. PubMed ID: 6812385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of citalopram as a monotherapy or as an adjunctive treatment to estrogen therapy for perimenopausal and postmenopausal women with depression and vasomotor symptoms.
    Soares CN; Poitras JR; Prouty J; Alexander AB; Shifren JL; Cohen LS
    J Clin Psychiatry; 2003 Apr; 64(4):473-9. PubMed ID: 12716252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and lipid metabolic effects of unopposed oestrogen and two oestrogen-progestogen regimens in post-menopausal women.
    Hirvonen E; Lipasti A; Mälkönen M; Kärkkäinen J; Nuntila J; Timonen H; Manninen V
    Maturitas; 1987 Apr; 9(1):69-79. PubMed ID: 2955205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-response and withdrawal effects on climacteric symptoms after hormonal replacement therapy. A placebo-controlled therapeutic trial.
    Jensen J; Christiansen C
    Maturitas; 1983 Aug; 5(2):125-33. PubMed ID: 6415364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of norethisterone in postmenopausal women on oestrogen replacement therapy: a model for the premenstrual syndrome.
    Magos AL; Brewster E; Singh R; O'Dowd T; Brincat M; Studd JW
    Br J Obstet Gynaecol; 1986 Dec; 93(12):1290-6. PubMed ID: 3801360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Climacteric symptoms after oral and percutaneous hormone replacement therapy.
    Jensen PB; Jensen J; Riis BJ; Rødbro P; Strøm V; Christiansen C
    Maturitas; 1987 Nov; 9(3):207-15. PubMed ID: 2963205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a continuous oestrogen-progestogen regimen for climacteric complaints.
    Mattsson LA; Cullberg G; Samsioe G
    Maturitas; 1982 Aug; 4(2):95-102. PubMed ID: 7121296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The menopause: benefits and risks of estrogen-progestogen replacement therapy.
    Gambrell RD
    Fertil Steril; 1982 Apr; 37(4):457-74. PubMed ID: 7040116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Menopause and estrogen replacement therapy.
    Stuenkel CA
    Psychiatr Clin North Am; 1989 Mar; 12(1):133-52. PubMed ID: 2652104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estradiol-intranasal: a review of its use in the management of menopause.
    Dooley M; Spencer CM; Ormrod D
    Drugs; 2001; 61(15):2243-62. PubMed ID: 11772138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of climacteric and postmenopausal women with 17-beta-oestradiol and norethisterone acetate.
    Furuhjelm M; Carlström K
    Acta Obstet Gynecol Scand; 1977; 56(4):351-61. PubMed ID: 602703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.